Drug intelligence / Profile preview

amikacin + cefepime

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

Amikacin + cefepime is a combination antibiotic therapy used primarily to manage serious bacterial infections. This combination pairs amikacin (an aminoglycoside antibiotic) with cefepime (a fourth-generation cephalosporin antibiotic) to provide broad-spectrum coverage against both Gram-positive and Gram-negative bacteria. The combination is particularly effective for empirical treatment of febrile neutropenia, hospital-acquired pneumonia, ventilator-associated pneumonia, complicated intra-abdominal infections (when combined with metronidazole), and complicated urinary tract infections[2].

Brand names: Nicpime-AM

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amikacin + cefepime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amikacin + cefepime.

Explore the full profile